Menu
← Oncology Approval Tracker
FDA DECISION ·
Ivra
melphalan hydrochloride · Apotex
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An IV melphalan presentation for palliative treatment of multiple myeloma in patients for whom oral therapy is unsuitable.
LAMPGEN ANALYSIS
Why it matters
This approval adds a parenteral presentation for a defined palliative myeloma use.
What research teams should watch
Record the route and treatment intent to distinguish this product's label from transplant-conditioning and liver-directed melphalan uses.
PRIMARY RECORDS